Jump to content

Deprescribing

From Wikipedia, the free encyclopedia

Reduce medication burden and harm

Deprescribing is a process of tapering or stopping medications to achieve improved health outcomes by reducing exposure to medications that are potentially either harmful or no longer required.[1] Deprescribing is important to consider with changing health and care goals over time, as well as polypharmacy and adverse effects.[2] Deprescribing can improve adherence, cost, and health outcomes but may have adverse drug withdrawal effects. More specifically, deprescribing is the planned and supervised process of intentionally stopping a medication or reducing its dose to improve the person's health or reduce the risk of adverse side effects. Deprescribing is usually done because the drug may be causing harm, may no longer be helping the patient, or may be inappropriate for the individual patient's current situation.[3][4] Deprescribing can help correct polypharmacy and prescription cascade.

Deprescribing is often done with people who have multiple long-term conditions (multimorbidity), older people, and people who have a limited life expectancy.[5] In all of these situations, certain medications may contribute to an increased risk of adverse events, and people may benefit from a reduction in the amount of medication taken. Deprescribing aims to reduce medication burden and harm while maintaining or improving quality of life. "Simply because a patient has tolerated a therapy for a long duration does not mean that it remains an appropriate treatment. Thoughtful review of a patient's medication regimen in the context of any changes in medical status and potential future benefits should occur regularly, and those agents that may no longer be necessary should be considered for a trial of medication discontinuation."[6]

The process of deprescribing is usually planned and supervised by healthcare professionals.[7] To some, the definition of deprescribing includes only completely stopping a medication, while to others, deprescribing also includes dose reduction, which can improve quality of life (minimize side effects) while maintaining benefits.[8]

History

[edit]

The world’s first published use of the term “deprescribing” was described in 2003 by Michael Woodward in his article titled ‘Deprescribing: Achieving Better Health Outcomes for Older People through Reducing Medications.' It was published in the Society of Hospital Pharmacists of Australia's flagship Journal of Pharmacy Practice and Research (JPPR).’[9][additional citation(s) needed]

Demographics

[edit]

Older people are the heaviest users of medications and frequently take five or more medications (polypharmacy). Polypharmacy is associated with increased risks of adverse events, drug interactions, falls, hospitalization, cognitive deficits,[better source needed] and mortality.[10] These effects are particularly seen in high-risk prescribing.[11] Thus, optimizing medication through targeted deprescribing is a vital part of managing chronic conditions, avoiding adverse effects and improving outcomes.

Evidence base

[edit]

Deprescribing is considered a potential intervention with reported safety and feasibility.[12][13] For a wide range of medications, including diuretics, blood pressure medication, sedatives, antidepressants, benzodiazepines and nitrates, adverse effects of deprescribing are rare.[14][15] While deprescribing has been shown to result in fewer medications, it is less certain if deprescribing is associated with significant changes in health outcomes.[12][16] Although it might be possible and safe to reduce the number of medicines that people use, reversing the potential harms associated with polypharmacy may not always be achievable.[17] Early evidence suggested that deprescribing may reduce premature death, leading to calls to undertake a double-blind study. A placebo-controlled, double-blind, randomized controlled trial was published in 2023. This study undertook deprescribing in people over 65 years living in residential aged care.[18] It found no change in mortality[19] and that, if implemented in all residential aged care facilities across Australia, it could save up to $16 million annually.[20]

Deprescribing medications may improve patient function, generate a higher quality of life, and reduce bothersome signs and symptoms. Deprescribing has been shown to reduce the number of falls people experience but not to change the risk of having the first fall.[12] Most health outcomes remain unchanged as an effect of deprescribing. The absence of a change has been viewed as a positive outcome, as the medications can often be safely withdrawn without altering health outcomes. This absence of an effect means that older people may not miss out on potentially beneficial effects of using medications due to deprescribing.[12]

Targeted deprescribing can improve adherence to other drugs.[5] Deprescribing can reduce the complexity of medication schedules. Complicated schedules are difficult for people to follow correctly.

The product information provided by drug companies provides much information on how to start medications and what to expect when using them. However, it provides little information on when and how to stop medications.[21] Research into deprescribing is accumulating, with two papers showing a rapid acceleration in using the word since 2015.[8][3]

In people with multiple long-term conditions and polypharmacy, deprescribing represents a complex challenge as clinical guidelines are usually developed for single conditions. In these cases, tools and guidelines like the Beers Criteria and STOPP/START could be used safely by clinicians, but not all patients might benefit from stopping their medication. There is a need for clarity about how much clinicians can do beyond the guidelines and the responsibility they need to take could help them prescribing and deprescribing for complex cases. Further factors that can help clinicians tailor their decisions to the individual are: access to detailed data on the people in their care (including their backgrounds and personal medical goals), discussing plans to stop a medicine already when it is first prescribed, and a good relationship that involves mutual trust and regular discussions on progress. Furthermore, longer appointments for prescribing and deprescribing would allow time to explain the process, explore related concerns, and support making the right decisions.[22][23]

A review analysed way to improve deprescribing in primary care. It concluded that clearly defined roles and responsibilities, with good communication between multidisciplinary team members, and pharmacists integrated within teams could aid deprescribing. Routine discussions about deprescribing when prescribing, with medication reviews tailored to patients’ needs and preferences could also help. Patients and informal carers should be involved in decisions, and trusted relationships should be built up with professionals allowing continuity of care. Clinicians would also benefit from training and education on deprescribing.[24][25]

Risks

[edit]

It is possible for the patient to develop adverse drug withdrawal events (ADWE).[26] These symptoms may be related to the original reason why the medication was prescribed, to withdrawal symptoms or to underlying diseases that medications have masked.[27] For some medications, ADWEs can generally be minimized or avoided by tapering the dose slowly and carefully monitoring for symptoms. Prescribers should be aware of which medications usually require tapering (such as corticosteroids and benzodiazepines) and which can be safely stopped suddenly (such as antibiotics and nonsteroidal anti-inflammatory drugs).

Monitoring

[edit]

Deprescribing requires detailed follow-up and monitoring, not unlike the attention required when starting a new medication. It is recommended that prescribers frequently monitor "relevant signs, symptom, laboratory or diagnostic tests that were the original indications for starting the medication," as well as for potential withdrawal effects.[15] The recommended schedule for monitoring during deprescribing is at two-week intervals.[28]

Resources to support deprescribing

[edit]

Implicit tools

[edit]

Several tools have been published to inform prescribers of inappropriate medications for various patient groups. The most common deprescribing algorithm is validated[29] and has been tested in two RCTs.[16] It is available for clinicians to identify medications that can be deprescribed.[29] It prompts clinicians to consider if it is (1) an inappropriate prescription, (2) adverse effects or interactions that outweigh symptomatic effects or potential future benefits, (3) drugs taken for symptom relief but the symptoms are stable, and (4) drug intended to prevent future severe events but the potential benefit is unlikely to be realized due to limited life expectancy. If the answer to any of the four prompts is yes, then the medication should be considered for deprescribing.

The CEASE algorithm prompts clinicians to consider if the treated condition remains a current concern for their patient.

The ERASE algorithm prompts clinicians to consider whether the treated condition still requires treatment.[30] The ERASE mnemonic stands for "evaluate diagnostic parameters," "resolved conditions," "ageing normally," "select targets," and "eliminate."

Explicit tools

[edit]

The Beers Criteria and the STOPP/START criteria present medications that may be inappropriate for use in older adults,[31] including drugs associated with high risk of adverse reactions for this population or lacking evidence for their benefits when safer and more effective alternatives exist.[32] Some countries, such as, Australia have their lists of Potentially Inappropriate Medicines.[33] For people with dementia, the Medication Appropriateness Tool for Comorbid Health Conditions in Dementia (MATCH-D)[34] can help clinicians identify when and what to consider deprescribing.[35]

Resources

[edit]

RxFiles, an academic detailing group based in Saskatchewan, Canada, has developed a tool to help long-term care providers identify potentially inappropriate medications in their residents.[36] Tasmanian Medicare Local has created resources to help clinicians deprescribe.[37] Theoretical Underpinnings of a Model to Reduce Polypharmacy and Its Negative Health Effects: Introducing the Team Approach to Polypharmacy Evaluation and Reduction (TAPER) is a framework to support practitioners in deprescribing.[38]

Practice changes to encourage deprescribing

[edit]

An expert working group concluded that integrated healthcare provided by multidisciplinary patient-centred teams was the most appropriate approach to promote deprescribing and improve appropriate medication use.[39] Deprescribing rounds in tertiary care hospitals have also been evaluated and shown to improve health-related outcomes.[40]

Barriers and enablers to deprescribing

[edit]

Barriers

[edit]

Although many trials have successfully resulted in a reduction in medication use, there are some barriers to deprescribing:

  • the prescriber's beliefs, attitudes, knowledge, skills, and behaviour[41]
  • the prescriber's work environment, including work setting, health system and cultural factors[41]
  • patients' fears about cessation or dislike of medications.[42]

Enablers

[edit]
  • the prescriber's beliefs, attitudes, knowledge, skills, and behaviour[41]
  • the prescriber's work environment, including work setting, health system and cultural factors[41]
  • the patient's agreement that deprescribing was appropriate,[42]
  • a structured process for cessation,[42]
  • the patients' need for influences or reasons to cease medication,[42]

The prescriber and patients were shown to have the most significant influence on each other rather than external influences. 9 out of 10 older people said they would be willing to stop one or more medications if their doctor said it was okay.

See also

[edit]

References

[edit]
  1. ^ Page A, Clifford R, Potter K, Etherton-Beer C (April 2018). "A concept analysis of deprescribing medications in older people". Journal of Pharmacy Practice and Research. 48 (2): 132–148. doi:10.1002/jppr.1361. S2CID 56510472.
  2. ^ Quek HW, Page A, Potter K, Etherton-Beer C (April 2023). "Deprescribing considerations for older people in general practice". Australian Journal of General Practice. 52 (4): 173–180. doi:10.31128/AJGP-08-22-6547. PMID 37021442. S2CID 257984022.
  3. ^ a b Reeve E, Gnjidic D, Long J, Hilmer S (December 2015). "A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice". British Journal of Clinical Pharmacology. 80 (6): 1254–1268. doi:10.1111/bcp.12732. PMC 4693477. PMID 27006985.
  4. ^ Thompson W, Farrell B (May 2013). "Deprescribing: what is it and what does the evidence tell us?". The Canadian Journal of Hospital Pharmacy. 66 (3): 201–202. doi:10.4212/cjhp.v66i3.1261. PMC 3694945. PMID 23814291.
  5. ^ a b Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN (May 2012). "Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes". Clinics in Geriatric Medicine. 28 (2): 237–253. doi:10.1016/j.cger.2012.01.006. PMID 22500541.
  6. ^ Linsky A, Simon SR (April 2013). "Reversing gears: discontinuing medication therapy to prevent adverse events". JAMA Internal Medicine. 173 (7): 524–525. doi:10.1001/jamainternmed.2013.4068. PMID 23459795.
  7. ^ Liacos M, Page AT, Etherton-Beer C (August 2020). "Deprescribing in older people". Australian Prescriber. 43 (4): 114–120. doi:10.18773/austprescr.2020.033. PMC 7450772. PMID 32921886.
  8. ^ a b Page A, Clifford R, Potter K, Etherton-Beer C (April 2018). "A concept analysis of deprescribing medications in older people". Journal of Pharmacy Practice and Research. 48 (2): 132–148. doi:10.1002/jppr.1361.
  9. ^ Woodward MC (2003). "Deprescribing: Achieving Better Health Outcomes for Older People through Reducing Medications". Journal of Pharmacy Practice and Research. 33 (4). Wiley: 323–328. doi:10.1002/jppr2003334323. ISSN 1445-937X.
  10. ^ Bloomfield HE, Greer N, Linsky AM, Bolduc J, Naidl T, Vardeny O, et al. (November 2020). "Deprescribing for Community-Dwelling Older Adults: a Systematic Review and Meta-analysis". Journal of General Internal Medicine. 35 (11): 3323–3332. doi:10.1007/s11606-020-06089-2. PMC 7661661. PMID 32820421.
  11. ^ Wang K, Alan J, Page AT, Dimopoulos E, Etherton-Beer C (September 2021). "Anticholinergics and clinical outcomes amongst people with pre-existing dementia: A systematic review". Maturitas. 151: 1–14. doi:10.1016/j.maturitas.2021.06.004. PMID 34446273.
  12. ^ a b c d Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD (September 2016). "The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis". British Journal of Clinical Pharmacology. 82 (3): 583–623. doi:10.1111/bcp.12975. PMC 5338123. PMID 27077231.
  13. ^ Page AT, Khalil H, Etherton-Beer C, Clifford R, Potter K (April 2014). "The efficacy of deprescribing interventions on health outcomes in people aged over 65 years: a systematic review protocol". JBI Database of Systematic Reviews and Implementation Reports. 12 (4): 124–134. doi:10.11124/jbisrir-2014-1394. ISSN 2202-4433.
  14. ^ Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG (2008). "Medication withdrawal trials in people aged 65 years and older: a systematic review". Drugs & Aging. 25 (12): 1021–1031. doi:10.2165/0002512-200825120-00004. PMID 19021301. S2CID 25414320.
  15. ^ a b Garfinkel D, Mangin D (October 2010). "Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy". Archives of Internal Medicine. 170 (18): 1648–1654. doi:10.1001/archinternmed.2010.355. PMID 20937924.
  16. ^ a b Potter K, Flicker L, Page A, Etherton-Beer C (March 2016). "Deprescribing in Frail Older People: A Randomised Controlled Trial". PLOS ONE. 11 (3): e0149984. Bibcode:2016PLoSO..1149984P. doi:10.1371/journal.pone.0149984. PMC 4778763. PMID 26942907.
  17. ^ Quek HW. "The effect of deprescribing interventions on mortality and health outcomes in older people: an updated systematic review and meta-analysis". British Journal of Clinical Pharmacology.
  18. ^ Quek HW, Etherton-Beer C, Page A, McLachlan AJ, Lo SY, Naganathan V, et al. (April 2023). "Deprescribing for older people living in residential aged care facilities: Pharmacist recommendations, doctor acceptance and implementation". Archives of Gerontology and Geriatrics. 107: 104910. doi:10.1016/j.archger.2022.104910. PMID 36565605.
  19. ^ Etherton-Beer C, Page A, Naganathan V, Potter K, Comans T, Hilmer SN, et al. (May 2023). "Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial-outcomes of the Opti-med study". Age and Ageing. 52 (5). doi:10.1093/ageing/afad081. PMC 10226731. PMID 37247404.
  20. ^ Okafor CE, Keramat SA, Comans T, Page AT, Potter K, Hilmer SN, et al. (March 2024). "Cost-Consequence Analysis of Deprescribing to Optimize Health Outcomes for Frail Older People: A Within-Trial Analysis". Journal of the American Medical Directors Association. 25 (3): 539–544.e2. doi:10.1016/j.jamda.2023.12.016. PMID 38307120.
  21. ^ Page A, Clifford R, Potter K, Etherton-Beer C (2018). "Informing deprescribing decisions in older people: does the Product Information contain advice on medication use for older people and medication withdrawal?". Journal of Pharmacy Practice and Research. 48 (2): 149–157. doi:10.1002/jppr.1362. S2CID 79794144.
  22. ^ "How to reduce medications for people with multiple long-term conditions". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2023-05-18. doi:10.3310/nihrevidence_57904. S2CID 258801327.
  23. ^ Reeve J, Maden M, Hill R, Turk A, Mahtani K, Wong G, et al. (July 2022). "Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis". Health Technology Assessment. 26 (32): 1–148. doi:10.3310/AAFO2475. PMC 9376985. PMID 35894932.
  24. ^ Radcliffe E, Servin R, Cox N, Lim S, Tan QY, Howard C, et al. (2023-09-25). "What makes a multidisciplinary medication review and deprescribing intervention for older people work well in primary care? A realist review and synthesis". BMC Geriatrics. 23 (1): 591. doi:10.1186/s12877-023-04256-8. ISSN 1471-2318. PMC 10519081. PMID 37743469.
  25. ^ "How to deprescribe in primary care". NIHR Evidence. 7 May 2024. doi:10.3310/nihrevidence_62994.
  26. ^ Graves T, Hanlon JT, Schmader KE, Landsman PB, Samsa GP, Pieper CF, et al. (October 1997). "Adverse events after discontinuing medications in elderly outpatients". Archives of Internal Medicine. 157 (19): 2205–2210. doi:10.1001/archinte.1997.00440400055007. PMID 9342997.
  27. ^ Woodward MC (December 2003). "Deprescribing: Achieving Better Health Outcomes for Older People through Reducing Medications". Journal of Pharmacy Practice and Research. 33 (4): 323–328. doi:10.1002/jppr2003334323. S2CID 73918568.
  28. ^ Quek HW, Etherton-Beer C, Page A, McLachlan AJ, Lo SY, Naganathan V, et al. (April 2023). "Deprescribing for older people living in residential aged care facilities: Pharmacist recommendations, doctor acceptance and implementation". Archives of Gerontology and Geriatrics. 107: 104910. doi:10.1016/j.archger.2022.104910. PMID 36565605. S2CID 254917543.
  29. ^ a b Page AT, Etherton-Beer CD, Clifford RM, Burrows S, Eames M, Potter K (2016-05-01). "Deprescribing in frail older people--Do doctors and pharmacists agree?". Research in Social & Administrative Pharmacy. 12 (3): 438–449. doi:10.1016/j.sapharm.2015.08.011. PMID 26453002.
  30. ^ Page A, Etherton-Beer C (May 2019). "Undiagnosing to prevent overprescribing". Maturitas. 123: 67–72. doi:10.1016/j.maturitas.2019.02.010. PMID 31027680.
  31. ^ Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D (February 2008). "STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation". International Journal of Clinical Pharmacology and Therapeutics. 46 (2): 72–83. doi:10.5414/cpp46072. PMID 18218287. S2CID 25532572.
  32. ^ Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH (2003-12-08). "Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts". Archives of Internal Medicine. 163 (22): 2716–2724. doi:10.1001/archinte.163.22.2716. PMID 14662625.
  33. ^ Wang KN, Etherton-Beer CD, Sanfilippo F, Page AT (February 2024). "Development of a list of Australian potentially inappropriate medicines using the Delphi technique". Internal Medicine Journal. doi:10.1111/imj.16322. PMID 38303674.
  34. ^ "MATCH-D Medication Appropriateness Tool for Comorbid Health conditions during Dementia". www.match-d.com.au. Retrieved 2023-05-31.
  35. ^ Page AT, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C (October 2016). "Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel". Internal Medicine Journal. 46 (10): 1189–1197. doi:10.1111/imj.13215. PMC 5129475. PMID 27527376.
  36. ^ "Long-Term Care & Residential Care: Evidence-Based Resources". RxFiles. January 2016.
  37. ^ "Deprescribing Documents now Available for Download". Consultant Pharmacy Services.
  38. ^ Mangin D, Lamarche L, Templeton JA, Salerno J, Siu H, Trimble J, et al. (September 2023). "Theoretical Underpinnings of a Model to Reduce Polypharmacy and Its Negative Health Effects: Introducing the Team Approach to Polypharmacy Evaluation and Reduction (TAPER)". Drugs & Aging. 40 (9): 857–868. doi:10.1007/s40266-023-01055-z. PMC 10450010. PMID 37603255.
  39. ^ Page AT, Cross AJ, Elliott RA, Pond D, Dooley M, Beanland C, et al. (October 2018). "Integrate healthcare to provide multidisciplinary consumer-centred medication management: report from a working group formed from the National Stakeholders' Meeting for the Quality Use of Medicines to Optimise Ageing in Older Australians". Journal of Pharmacy Practice and Research. 48 (5): 459–466. doi:10.1002/jppr.1434. S2CID 81405354.
  40. ^ Edey R, Edwards N, Von Sychowski J, Bains A, Spence J, Martinusen D (February 2019). "Impact of deprescribing rounds on discharge prescriptions: an interventional trial". International Journal of Clinical Pharmacy. 41 (1): 159–166. doi:10.1007/s11096-018-0753-2. PMID 30478496. S2CID 53730423.
  41. ^ a b c d Anderson K, Stowasser D, Freeman C, Scott I (December 2014). "Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis". BMJ Open. 4 (12): e006544. doi:10.1136/bmjopen-2014-006544. PMC 4265124. PMID 25488097.
  42. ^ a b c d Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD (October 2013). "Patient barriers to and enablers of deprescribing: a systematic review". Drugs & Aging. 30 (10): 793–807. doi:10.1007/s40266-013-0106-8. PMID 23912674. S2CID 13317143.

Further reading

[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Deprescribing&oldid=1242311590"